IceCure Medical Ltd. (NASDAQ:ICCM) Stock Has Consensus Target Price of $52.50 According to Brokerages

IceCure Medical Ltd. (NASDAQ:ICCM) has earned an average rating of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $52.50.

A number of research firms recently weighed in on ICCM. Zacks Research downgraded shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th.

IceCure Medical Stock Performance

NASDAQ ICCM opened at $1.57 on Thursday. IceCure Medical has a 52 week low of $1.55 and a 52 week high of $42.00. The stock’s 50 day moving average price is $2.39 and its two-hundred day moving average price is $5.84. The stock has a market capitalization of $5.39 million, a price-to-earnings ratio of -0.18 and a beta of 0.43.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%.The business had revenue of $0.91 million for the quarter. On average, equities research analysts forecast that IceCure Medical will post -4.61 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.